You are in the accessibility menu

Please use this identifier to cite or link to this item: http://acervodigital.unesp.br/handle/11449/7660
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDe Rosa, Helene J.-
dc.contributor.authorBaldan, Helen M.-
dc.contributor.authorBrunetti, Iguatemy Lourenço-
dc.contributor.authorXimenes, Valdecir Farias-
dc.contributor.authorMachado, Rosangela G. P.-
dc.date.accessioned2014-05-20T13:24:34Z-
dc.date.accessioned2016-10-25T16:45:17Z-
dc.date.available2014-05-20T13:24:34Z-
dc.date.available2016-10-25T16:45:17Z-
dc.date.issued2007-09-01-
dc.identifierhttp://dx.doi.org/10.1002/bdd.557-
dc.identifier.citationBiopharmaceutics & Drug Disposition. Chichester: John Wiley & Sons Ltd, v. 28, n. 6, p. 291-296, 2007.-
dc.identifier.issn0142-2782-
dc.identifier.urihttp://hdl.handle.net/11449/7660-
dc.identifier.urihttp://acervodigital.unesp.br/handle/11449/7660-
dc.description.abstractHepatotoxicity is the main concern during tuberculosis chemotherapy with the first-line drugs isoniazid (INH), rifampicin (RMP) and pyrazinamide (PYR). Since these hepatotoxic events have been associated with INH metabolites, the study aimed to measure the area under curve (AUC) parameter for INH and its metabolites acetylisoniazid (AcINH), hydrazine (Hz) and acetylhydrazine (AcHz), when groups of rats were pre-treated for 21 days with INH alone or in combination with RMP and/or PYR, in the following amounts per kg body weight: INH 100 mg; INH 100 mg + RMP 100 mg; INH 100 mg + PYR 350 mg; INH 100 mg + PYR 350 mg + RMP 100 mg. It was found that co-administration of RMP, PYR and RMP + PYR caused a significant decrease in the AUC for INH. Co-administration of PYR was the only treatment that caused a significant increase in the AUC for Hz and a decrease in the AUC for its acetylated product AcHz. The AUC for AcINH was not significantly altered in any experimental group. In conclusion, the increased metabolism of INH in all the drug combinations and the significantly higher production of Hz in the group INH + PYR might be linked with exacerbated hepatotoxic effects of these drug associations. Copyright (c) 2007 John Wiley & Sons, Ltd.en
dc.format.extent291-296-
dc.language.isoeng-
dc.publisherWiley-Blackwell-
dc.sourceWeb of Science-
dc.subjectisoniazidpt
dc.subjectrifampicinpt
dc.subjectpyrazinamidept
dc.subjectacetylisoniazidpt
dc.subjectacetylhydrazinept
dc.titleThe effect of pyrazinamide and rifampicin on isoniazid metabolism in ratsen
dc.typeoutro-
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)-
dc.description.affiliationUniv Estadual Paulista, Dept Principios Ativos Nat & Toxicol, Araraquara, SP, Brazil-
dc.description.affiliationUniv Estadual Paulista, Fac Ciências Farmaceut, Dept Analises Clin, Araraquara, SP, Brazil-
dc.description.affiliationUniv Estadual Paulista, Fac Ciências, Dept Quim, Bauru, SP, Brazil-
dc.description.affiliationUnespUniv Estadual Paulista, Dept Principios Ativos Nat & Toxicol, Araraquara, SP, Brazil-
dc.description.affiliationUnespUniv Estadual Paulista, Fac Ciências Farmaceut, Dept Analises Clin, Araraquara, SP, Brazil-
dc.description.affiliationUnespUniv Estadual Paulista, Fac Ciências, Dept Quim, Bauru, SP, Brazil-
dc.identifier.doi10.1002/bdd.557-
dc.identifier.wosWOS:000249836800004-
dc.rights.accessRightsAcesso restrito-
dc.relation.ispartofBiopharmaceutics & Drug Disposition-
Appears in Collections:Artigos, TCCs, Teses e Dissertações da Unesp

There are no files associated with this item.
 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.